Tag Archives: FDA

Oncology

Oncology Biosimilars: Opportunity or Not?

Posted on by John Santilli

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Continue reading →
Specialty Drug

Specialty Drug Wave Hitting Medical and Pharmacy Plans Harder: Trends versus reliable benefit strategy to handle the impact through 2020?

Posted on by John Santilli

Specialty Drug Wave Hitting Medical and Pharmacy Plans Harder: Trends versus reliable benefit strategy to handle the impact through 2020?The U.S. now has two different markets resulting from implementation of the Affordable Care Act (ACA) and resultant trends. Related to specialty or biological drugs, public sector CMS’s forecast of drug spending is somewhat counterintuitive, given […]

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: FDA warns of rare brain infection with MS drug Tecfidera

Posted on by John Santilli

New oral therapies Biogen Idec’s dimethyl fumarate is one of the new market entrants driving the shift to oral therapy growth in MS treatment, according to John Santilli of Access Market Intelligence, which provides business information to the pharmaceutical and healthcare industries. “Although this is Tecfidera’s first incident tied to PML use in more than 100,000 […]

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: FDA approves Cyramza in combination with paclitaxel for advanced gastric cancer after prior chemotherapy

Posted on by John Santilli

“Cyramza, approved earlier this year for stomach cancer, is a key product in Lilly’s oncology portfolio,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. “With the colorectal cancer market becoming increasingly crowded, Lilly will need to review the pricing strategy for Cyramza to make sure the drug remains competitive […]

Continue reading →
Clinical Collaborations

Clinical trial collaborations – an idea whose time has come

Posted on by John Santilli

The cost and time commitment to develop new drugs has increased significantly over the last few decades. A variety of factors come into play, but on average, in terms of total expenditures, it has taken from $3 to $5 billion and up to 15 years to bring a new drug to market. Even after all […]

Continue reading →